The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations
Wall Street Futures Slip as Oracle Earnings Miss Reignites AI Spending Concerns
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth
CVS Health Signals Strong 2026 Profit Outlook Amid Turnaround Progress
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound 



